Charles L. Sawyers, M.D., Member of the Board of Directors
Charles L. Sawyers, M.D., Member of the Board of Directors

Charles L. Sawyers, M.D.

Board member since 2013

Charles L. Sawyers, M.D.

Board member since 2013

Charles L. Sawyers, M.D., Member of the Board of Directors

Nationality: American | Year of birth: 1959

Charles L. Sawyers is a highly accomplished expert and leader in cancer research. As a physician and prominent scientist, he has a deep understanding of the benefits of drugs for patients and society at large, and the importance of access to medicines. Dr. Sawyers co-developed the Novartis cancer drug Gleevec/ Glivec and has received numerous honors and awards, including the Lasker-DeBakey Clinical Medical Research Award.

Professional experience

  • Chair of the Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, US (2006–present)
  • Professor of medicine (2008–present), and professor of cell and developmental biology (2011–present), Weill Cornell Graduate School of Medical Sciences, US
  • Investigator, Howard Hughes Medical Institute, US (2002–2006 and 2008–present)
  • Associate chief, Division of Hematology-Oncology, University of California, Los Angeles, US (1996–2006)

Mandates

  • Member, National Academy of Medicine, US
  • Member, National Academy of Sciences, US
  • Investigator, Howard Hughes Medical Institute, US
  • Science advisor for the following US companies: Agios Pharmaceuticals Inc.; Arsenal Capital Partners; BeiGene Ltd.; Blueprint Medicines Corp.; Foghorn Therapeutics Inc.; Housey Pharmaceutical Research Laboratories; KSQ Therapeutics Inc.; Nextech Invest Ltd.; ORIC Pharmaceuticals Inc.; PMV Pharmaceuticals Inc.; The Column Group
  • Member, National Cancer Advisory Board, US (2012–2020)
  • President, American Association for Cancer Research, US (2013–2014)

Education

  • Doctor of medicine, Johns Hopkins University School of Medicine, US
  • Bachelor of Arts, Princeton University, US

Key skills

  • Medicine/healthcare/R&D
  • Leadership/management
  • Environmental, social and governance (ESG)